Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956044 · ClinicalTrials.gov registry record · Phase 1
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
A Phase 1 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02956044 is a Phase 1 study that has completed, run by Theracos. The registered enrollment target is 54 participants.
The verdict
NCT02956044, a Phase 1 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Glimepiride
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956044
The ClinicalTrials.gov registry entry for NCT02956044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT02956044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956044 about?
NCT02956044 is a clinical study titled "Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin". The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is to...
What is the current status of trial NCT02956044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2016-11. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02956044?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), Glimepiride (DRUG), Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT02956044?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.